C011P: Infliximab Biosimilar, TNF alpha Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.C072P: Envafolimab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant humanized nanobody (VHH-hIgG1 Fc fusion protein) .
Specificity/Sensitivity: The in vivo grade envafolimab specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by envafolimab.C022P: Eculizumab Biosimilar, Human C5 Monoclonal Antibody
Recombinant Humanized IgG2/4 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays.C004P: Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Recombinant Humanized IgG2 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.C030P: Daratumumab Biosimilar, CD38 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade daratumumab biosimilar specifically binds to the human CD38 protein, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by daratumumab.C100P: Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody
Recombinant Human IgG1 Kappa Monoclonal Antibody.
Specificity/Sensitivity: The casirivimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by casirivimab.C001P: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Specificity/Sensitivity: The monoclonal antibody bevacizumab biosimilar specifically binds to the human VEGF-A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.C003P: Adalimumab Biosimilar, TNF alpha Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.C019P: BeneFIX Biosimilar, Recombinant Factor IX
The yield of BeneFIX biosimilar from the CHO stable cell line was above 20 IU/mL in a 15 liter manufacturing.
C018: Advate / Kogenate Biosimilar Stable Cell Line
The yield of Advate / Kogenate Biosimilar from the CHO stable cell line was above 60 IU/ml in a 50 liter manufacturing.